Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 19, Issue 1, 2007, Pages 138-145

  Fumaz, C R ^a,b,c   Munoz Moreno J A ^a,b,c   Ballesteros, A L ^a,b,c   Paredes, R ^a,b   Ferrer, M J ^b   Salas, A ^b   Fuster, D ^a,b,c   Masmitja E ^a,d   Perez Alvarez N ^a,d   Gomez G ^d   Tural, C ^b   Clotet, B ^a,b,e  

^a Lluita Contra la SIDA Foundation   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^e IrsiCaixa Foundation   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CITALOPRAM; CLORAZEPATE DIPOTASSIUM; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; RISPERIDONE;

ADULT; ALCOHOLISM; AMNESIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; COCAINE DEPENDENCE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DRUG DEPENDENCE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG HYPERSENSITIVITY; EMOTION; FATIGUE; FEMALE; HEALTH CARE QUALITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MANIA; MENTAL DISEASE; MENTAL HEALTH; NEUTROPENIA; OBSERVATIONAL STUDY; PANCREATITIS; PATIENT COMPLIANCE; PERCEPTION; PHYSICAL ACTIVITY; PHYSICAL DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; SYMPTOM; THROMBOCYTOPENIA;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; MALE; MENTAL DISORDERS; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECURRENCE; RIBAVIRIN; TREATMENT REFUSAL;

EID: 33845210214     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540120600645539     Document Type: Article

References (31)

1. Ammassari, A., Antinori, A., Aloisi, M.S., Trotta, M.P., Murri, R., Bartoli, L., et al. (2004). Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics, 45, 394-402.
2. Beck, A.T., Rush, A.J., Shaw, B.F., & Emery, G. (1979). Cognitive Therapy of Depression. New York: Guilford Press.
3. Bianchi, G., Loguercio, C., Sgarbi, D., Abbiati, R., Chen, C.H., Di Pierro, M., et al. (2000). Reduced quality of life in patients with chronic hepatitis C: effects of interferon treatment. Digestive and Liver Disease, 32, 398-405.
4. Bonaccorso, S., Puzella, A., Marino, V., Pasquini, M., Biondi, M., Artini, M., et al. (2001). Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Research, 105, 45-55.
5. Cohen, M., Hoffman, R.G., Cromwell, C., Schmeidler, J., Ebrahim, F., Carrera, G., et al. (2002). The prevalence of distress in persons with human immunodeficiency virus infection. Psychosomatics, 43, 10-15.
6. Dimatteo, M.R., Lepper, H.S., & Croghan, T.W. (2000). Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effect of anxiety and depression on patient adherence. Archives of Internal Medicine, 160, 2101-107.
7. Fleming, C.A., Christiansen, D., Nunes, D., Heeren, T., Thornton, D., Horsburgh, C.R. Jr., et al. (2004). Health-related quality of life of patients with HIV disease: impact of hepatitis C coinfection. Clinical Infectious Diseases, 38, 572-78.
8. Fried, M.W. (2002). Side effects of therapy for hepatitis C and their management. Hepatology, 36(Suppl 1), S237-244.
9. Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Goncales, F.L. Jr, et al. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. The New England Journal of Medicine, 347, 975-82.
10. Hauser, P., Khosla, J., Aurora, H., Laurin, J., Kling, M.A., Hill, J., et al. (2002). A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Molecular Psychiatry, 7, 942-47.
11. Hsiung, P.C., Fang, C.T., Chang, Y.Y., Chen, M.Y., & Wang, J.D. (2005). Comparison of WHOQOL-bREF and SF-36 in patients with HIV infection. Quality of Life Research, 14, 141-50.
12. Johnson, M.O., Stallworth, T., & Neilands, T.B. (2003). The drugs or the disease?. Causal attributions of symptoms held by HIV-positive adults on HAART. AIDS and Behavior, 7, 109-17.
13. Kraus, M.R., Schafer, A., Csef, H., Faller, H., Mork., H., & Scheurlen, M. (2001). Compliance with therapy in patients with chronic hepatitis C: associations with psychiatric symptoms, interpersonal problems, and mode of acquisition. Digestive Diseases and Science, 46, 2060-65.
14. Laguno, M., Blanch, J., Murillas, J., Blanco, J.L., Leon, A., Lonca, M., et al. (2004). Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C. Antiviral Therapy, 9, 905-909.
15. Laguno, M., Murillas, J., Blanco, J.L., Martinez, E., Miquel, R., Sanchez-Tapias, J.M., et al. (2004). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS, 18, 27-36.
16. Lucas, G.M., Chaisson, R.E., & Moore, R.D. (1999). Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Annals of Internal Medicine, 131, 81-87.
17. Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R., et al. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 358, 958-65.
18. Moreno, L., Quereda, C., Moreno, A., Perez-Elias, M.J., Antela, A., Casado, J.L., et al. (2004). Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS, 18, 67-73.
19. Musselman, D.L., Lawson, D.H., Gumnick, J.F., Manatunga, A.K., Penna, S., Goodkin, R.S., et al. (2001). Paroxetine for the prevention of depression induced by high-dose interferon alfa. New England Journal of Medicine, 344, 961-66.
20. Myers, R.P., Benhamou, Y., Bochet, M., Thibault, V., Mehri, D., & Poynard, T. (2004). Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-coinfected non-responders and relapsers to IFN-based therapy. AIDS, 18, 75-79.
21. Paterson, D.L., Swindells, S., Mohr, J., Brester, M., Vergis, E.N., Squier, C., et al. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133, 21-30.
22. Pérez-Olmeda, M., Núñez, M., Romero, M., Gonzalez, J., Castro, A., Arribas, Jr., et al. (2003). Pegylated IFN-a 2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS, 17, 1023-28.
23. Phillips, K.D., Sowell, R.L., Rojas, M., Tavakoli, A., Fulk, L.J., & Hand, G.A. (2004). Physiological and psychological correlates of fatigue in HIV disease. Biological Research for Nursing, 6, 59-74.
24. Russo, M.W., & Fried, M.W. (2003). Side effects of therapy for chronic hepatitis C. Gastroenterology, 124, 1711-719.
25. Schaefer, M., Schmidt, F., Folwaczny, C., Lorenz, R., Martin, G., Schindlbeck, N., et al. (2003). Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology, 37, 443-51.
26. Sherman, K.E. (2004). HCV and HIV: a tale of two viruses. Reviews in gastroenterological disorders, 4(Suppl 1), 48-54.
27. Starace, F., Ammassari, A., Trotta, M.P., Murri, R., De Longis, P., Izzo, C., et al. (2002). Depression is a risk factor for supoptimal adherence to highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 31(Suppl 3), S136-S139.
28. Torriani, F.J., Rodriguez-Torres, M., Rockstroh, J.K., Lissen, E., Gonzalez-Garcia, J., Lazzarin, A., et al. (2004). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New England Journal of Medicine, 351, 438-50.
29. Tuldra, A., Fumaz, C.R., Ferrer, M.J., Bayes, R., Arno, A., Balague, M., et al. (2000). Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 25, 221-28.
30. Vázquez, C., & Sanz, J. (2000). Adaptación española del Inventario de Depresión de Beck (1978): propiedades psicométricas y clínicas en muestras clínicas y en población general. In A. Bulbena, G. Berrios, & P. Fernández de Larrinoa (Eds.), Medición clínica en psiquiatría y psicología (pp. 291-93). Barcelona: Masson S.A.
31. Ware, J.J./fnm〉, & Sherbourne, C.D. (1992). The MOS 36-item short-form health survey (SF-36). Conceptual framework and item selection. Medical Care, 30, 473-83.